• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding

    9/16/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVDL alert in real time by email

    A Media Snippet accompanying this announcement is available by clicking on this link.

    DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of collaboration and dedicated support for early-career sleep researchers and future sleep physicians.

    In 2021, Avadel became the Young Investigator Research Forum's (YIRF) inaugural corporate sponsor. Thanks to support from Avadel and other companies, YIRF has empowered dozens of trainees and junior faculty in sleep and circadian science, providing them with mentorship, grant-writing training, and networking opportunities that have become a vital steppingstone for launching successful research careers.

    This past June, Avadel was the lead sponsor of the AASM Fellow Boot Camp which is funded by the AASM Foundation. The boot camp is held annually in conjunction with the SLEEP Meeting and it is exclusively designed for residents and physicians who have matched into a Sleep Medicine Fellowship program that began in July 2025. The AASM Foundation funds the Fellow Boot Camp with the support of Avadel because both organizations have a shared commitment in providing fellows with baseline skills and knowledge needed to excel during their fellowship year.

    Avadel's contributions over the past five years have also played a pivotal role in strengthening the AASM Foundation's ability to fund innovative research and partnerships with patient advocacy groups including Wake Up Narcolepsy and the Hypersomnia Foundation. Since 2022, the AASM Foundation has partnered with these organizations to award five grants totaling $1.7 million for projects addressing central disorders of hypersomnolence.

    R. Nisha Aurora, MD, MHS, Past President, AASM Foundation, had this to say about collaborations with Wake Up Narcolepsy and the Hypersomnia Foundation, "Collaborating with organizations can really help advance research in sleep medicine. It's encouraging to see funding being directed toward important projects that address gaps in sleep medicine."

    "We are incredibly proud of our five-year partnership with the AASM Foundation and the meaningful impact we've made together in advancing sleep medicine research," said Jennifer Gudeman, Pharm.D., Senior Vice President, Medical and Clinical Affairs of Avadel. "Supporting early-career researchers aligns with our core belief that addressing unmet medical needs ultimately improves outcomes for patients living with sleep disorders — and investing in the next generation of sleep specialists is essential for driving this innovation in patient care. We look forward to continuing this vital work with the AASM Foundation as we strive to accelerate the science of sleep medicine."

    Looking to the future, the AASM Foundation is excited to continue collaborating with Avadel and others on a common goal: promote the research and discovery of new ways to improve the lives of people with sleep disorders.

    About the AASM Foundation

    The AASM Foundation is the official philanthropic arm of the American Academy of Sleep Medicine. Our values, programs, and purpose are focused on investing in people, research, and communities to improve the sleep health of all people.

    About Avadel Pharmaceuticals plc 

    Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZTM, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.

    Investor Contact:

    Austin Murtagh

    Precision AQ

    [email protected] 

    (212) 698-8696

    Media Contact:

    Alyssa Ramirez

    Real Chemistry

    [email protected] 



    Primary Logo

    Get the next $AVDL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVDL

    DatePrice TargetRatingAnalyst
    10/23/2025$20.00Buy → Neutral
    H.C. Wainwright
    9/3/2025$16.00Equal Weight
    Wells Fargo
    7/18/2025$22.00Buy
    H.C. Wainwright
    2/11/2025$12.00Buy
    Deutsche Bank
    6/12/2024$27.00Buy
    Rodman & Renshaw
    3/5/2024$27.00 → $29.00Outperform
    Oppenheimer
    3/5/2024$21.00 → $25.00Buy
    H.C. Wainwright
    3/5/2024$20.00 → $22.00Buy
    Needham
    More analyst ratings

    $AVDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES  —     Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)—     Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton—     Expected to be Immediately Accretive and Enhance Profitability Upon Closing—     Positions the Combined Organization to Accelerate Inn

    10/22/25 7:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

    DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. ("Jazz"). Under the primary terms of the settlement agreement, Avadel and Jazz will dismiss their respective lawsuits with prejudice. Furthermore, Jazz agrees to grant Avadel the following: A perpetual, worldwide license to any past, present, or future patents that could be asserted against LUMRYZ for any and all present and future indications, strengths, conditions of use, dosages, doses, dosage forms, and presentations.Jazz will make a p

    10/22/25 6:30:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the

    10/13/25 4:05:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palczuk Linda

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    9/15/25 7:54:41 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Glass Geoffrey Michael

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    9/15/25 7:53:58 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccamish Mark Anthony was granted 11,000 units of Ordinary Shares, increasing direct ownership by 100% to 22,000 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:10:52 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    SEC Filings

    View All

    SEC Form DEFA14A filed by Avadel Pharmaceuticals plc

    DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    10/22/25 5:26:39 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Avadel Pharmaceuticals plc

    DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    10/22/25 9:29:59 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    10/22/25 9:29:28 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avadel Pharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Avadel Pharmaceuticals from Buy to Neutral and set a new price target of $20.00

    10/23/25 7:39:15 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Avadel Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Avadel Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00

    9/3/25 8:27:31 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Avadel Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    7/18/25 9:08:21 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/22/25 4:13:34 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:24:12 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:22:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Leadership Updates

    Live Leadership Updates

    View All

    Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

    DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. "Susan is an accomplished biopharma executive with a track record of strategic leadership and excellence in commercializing innovative medicines," said Gregory J. Divis, Chief Executive Officer of Avadel. "Her expertise will be invaluable at this critical

    5/13/25 4:15:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

    DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build

    2/24/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

    DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin

    1/22/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES  —     Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)—     Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton—     Expected to be Immediately Accretive and Enhance Profitability Upon Closing—     Positions the Combined Organization to Accelerate Inn

    10/22/25 7:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

    DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are

    7/31/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/14/24 6:10:30 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:58:54 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:00:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care